Dr. Tariq Malik, M.D. Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 115 W Silver St, Westfield, MA 01085 Phone: 413-572-4400 |
Dr. Mehdi Pajouh, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 48 E Silver St, Ste 4, Westfield, MA 01085 Phone: 413-562-8088 Fax: 413-562-8006 |
Dr. Abendra B. Naidoo, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 48 East Silver Street, Suite 4, Westfield, MA 01085 Phone: 413-562-8088 Fax: 413-562-8006 |
Dr. Shantilal Nanji Kenia, M.D., FACC Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 27 Lady Slipper Cir, Westfield, MA 01085 Phone: 413-977-6590 Fax: 413-562-0907 |
News Archive
The New York Times also notes that many of these new Medicaid beneficiaries are people who have not had insurance before. Meanwhile, news outlets continue to track developments regarding how governors continue to wrestle with Medicaid decisions - including those in Virginia, Michigan and Maine. Also in the news, a problem with Maryland's Medicaid enrollment.
Researchers have conducted a study showing substantial reductions in the number of people attending primary care services for key physical and mental health conditions in the UK since lockdown was introduced on March 23rd this year.
Neuralstem, Inc. (NYSE MKT: CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) were published in the peer-reviewed journal, "Annals of Neurology".
There is no significant difference between an over-the-counter decongestant and a prescription medication that costs almost four times as much in relieving hay fever symptoms, report researchers from the University of Chicago in the February issue of Archives of Otolaryngology - Head & Neck Surgery.
Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.
› Verified 6 days ago